Show simple item record

dc.contributor.supervisor Gibson, Spencer (Biochemistry and Medical Genetics) Griffith, Jane (Community Health Sciences) en_US
dc.contributor.author Beiggi, Sara
dc.date.accessioned 2014-04-15T18:18:54Z
dc.date.available 2014-04-15T18:18:54Z
dc.date.issued 2013- en_US
dc.identifier.citation Beiggi S, Johnston JJ, Seftel MD, Pitz MW, Kumar R, Banerji V, et al. Increased risk of second malignancies in Chronic Lymphocytic Leukemia patients as compared with Follicular Lymphoma patients: A Canadian population-based study. Br J Cancer. 2013 en_US
dc.identifier.uri http://hdl.handle.net/1993/23508
dc.description.abstract A previous population-based study of survival in Chronic Lymphocytic Leukemia (CLL) patients in the province of Manitoba demonstrated a lower five-year relative survival among CLL patients compared with the age- and gender-adjusted general population. This decreased relative survival was most pronounced among elderly male CLL patients. In this study, we have demonstrated that the reduced five-year relative survival observed in CLL patients compared to the general population of Manitoba may partially be attributed to increased risk of second cancers and non-referral to specialized CLL clinics. The increased risk of second cancers in CLL patients compared to Follicular Lymphoma (FL), a similar indolent B cell malignancy, was only observed after CLL diagnosis indicating that a CLL-specific factor may be responsible for the increased risk of second cancers in these patients. The risk of second cancers is independent of treatment and surveillance bias but is further increased with chemotherapy. A superior outcome in CLL patients who have been referred to the CancerCare Manitoba (CCMB) specialized CLL clinic was observed that was independent of age, gender, treatment and history of previous cancers. This superior outcome was most pronounced in the elderly CLL patients. We propose that CLL patients should be referred to CLL-specific hematologists and, where not possible, that guidelines created by such experts be followed. Appropriate screening for second cancers should be performed during routine follow up of CLL patients. en_US
dc.publisher British Journal of Cancer (Nature Group) en_US
dc.rights info:eu-repo/semantics/openAccess
dc.subject Epidemiology en_US
dc.subject Chronic Lymphocytic Leukemia (CLL) en_US
dc.subject Small Lymphocytic Lymphoma (SLL) en_US
dc.subject Follicular Lymphoma (FL) en_US
dc.subject Non-Melanoma Skin Cancers (NMSCs) en_US
dc.subject Population-based study en_US
dc.subject Second malignancies en_US
dc.subject Specialized CLL clinic en_US
dc.subject Referral en_US
dc.subject Outcome en_US
dc.title Epidemiological study of chronic lymphocytic leukemia (CLL) in the province of Manitoba, Canada en_US
dc.type info:eu-repo/semantics/doctoralThesis
dc.degree.discipline Biochemistry and Medical Genetics en_US
dc.contributor.examiningcommittee Evans, Jane (Biochemistry and Medical Genetics) Banerji, Versha (Biochemistry and Medical Genetics) Johnston, James (Internal Medicine) Pitz, Marshall (Internal Medicine) Fritschi, Lin (University of Western Australia) en_US
dc.degree.level Doctor of Philosophy (Ph.D.) en_US
dc.description.note October 2014 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics